Anti-vWF Nanobody: Phase II started

Ablynx began a single-blind, placebo-controlled, international Phase II trial in 110 patients to evaluate a single 10 mg IV bolus of anti-vWF Nanobody prior to plasma exchange, followed by 10 mg once-...